Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Clozaril
Clozapine · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Clozapine | DRUG | - |
Inclusion Criteria: * Diagnosed as schizophrenia * Not responded to at least two atypical antipshychotics launched in Japan * Inpatient Exclusion Criteria: * Low white blood cell count * Significant heart diseases * Diabetes mellitus Other protocol-defined exclusion criteria may apply.
Top 15 of 16 competitors
Clozapine is used for schizophrenia, including treatment-resistant schizophrenia. It is a small molecule developed by Novartis AG under ticker NVS. The clinical program includes Phase 3 and Phase 2 studies in patients with treatment-resistant schizophrenia, with a minimum age of 18 years and both sexes eligible.
Clozapine targets DRD2 and HTR2A. It acts as an antagonist at these receptors, meaning it blocks dopamine D2 and serotonin 5-HT2A receptor activity. This target profile is the basis of its pharmacological action in schizophrenia.
Clozapine is developed by Novartis AG, which trades under the ticker NVS. The company is responsible for the clinical development program in schizophrenia.
Clozapine is in Phase 3 development for schizophrenia. It is an investigational small molecule and has not been approved based on the data described here. The program includes two completed trials, one Phase 3 and one Phase 2, with no active trials currently listed.
Clozapine has been studied in two completed trials: NCT00250575, a Phase 3 safety and efficacy study in treatment-resistant schizophrenia conducted in Japan with 43 patients, and NCT00154258, a Phase 2 long-term study in treatment-resistant schizophrenia with 19 patients. Both enrolled adults 18 years and older.